Xenetic Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.5
- Today's High:
- $4.72
- Open Price:
- $4.625
- 52W Low:
- $2.401
- 52W High:
- $7.7
- Prev. Close:
- $4.63
- Volume:
- 5632
Company Statistics
- Market Cap.:
- $7.10 million
- Book Value:
- 7.748
- Revenue TTM:
- $2.16 million
- Operating Margin TTM:
- -209.65%
- Gross Profit TTM:
- $1.16 million
- Profit Margin:
- -194.34%
- Return on Assets TTM:
- -19.36%
- Return on Equity TTM:
- -30.99%
Company Profile
Xenetic Biosciences Inc had its IPO on 2014-06-30 under the ticker symbol XBIO.
The company operates in the Healthcare sector and Biotechnology industry. Xenetic Biosciences Inc has a staff strength of 4 employees.
Stock update
Shares of Xenetic Biosciences Inc opened at $4.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.5 - $4.72, and closed at $4.54.
This is a -1.94% slip from the previous day's closing price.
A total volume of 5,632 shares were traded at the close of the day’s session.
In the last one week, shares of Xenetic Biosciences Inc have increased by +3.89%.
Xenetic Biosciences Inc's Key Ratios
Xenetic Biosciences Inc has a market cap of $7.10 million, indicating a price to book ratio of 0.4335 and a price to sales ratio of 3.6145.
In the last 12-months Xenetic Biosciences Inc’s revenue was $2.16 million with a gross profit of $1.16 million and an EBITDA of $-5746008. The EBITDA ratio measures Xenetic Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xenetic Biosciences Inc’s operating margin was -209.65% while its return on assets stood at -19.36% with a return of equity of -30.99%.
In Q2, Xenetic Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 56.2%.
Xenetic Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xenetic Biosciences Inc’s profitability.
Xenetic Biosciences Inc stock is trading at a EV to sales ratio of 0.1167 and a EV to EBITDA ratio of 1.0799. Its price to sales ratio in the trailing 12-months stood at 3.6145.
Xenetic Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $12.75 million
- Total Liabilities
- $871315.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Xenetic Biosciences Inc ended 2024 with $12.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.75 million while shareholder equity stood at $11.88 million.
Xenetic Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $871315.00 in other current liabilities, 1536.00 in common stock, $-191007135.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.73 million and cash and short-term investments were $10.73 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Xenetic Biosciences Inc’s total current assets stands at $12.04 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $221281.00 and inventory worth $0.
In 2024, Xenetic Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Xenetic Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.54
- 52-Week High
- $7.7
- 52-Week Low
- $2.401
- Analyst Target Price
- $40
Xenetic Biosciences Inc stock is currently trading at $4.54 per share. It touched a 52-week high of $7.7 and a 52-week low of $7.7. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $3.86 and 200-day moving average was $4.11 The short ratio stood at 0.47 indicating a short percent outstanding of 0%.
Around 1405% of the company’s stock are held by insiders while 381.1% are held by institutions.
Frequently Asked Questions About Xenetic Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.